

Dr. Jennifer Brogdon is currently Director of Exploratory Immuno-Oncology at Novartis Institutes for BioMedical Research in Cambridge, MA where she leads a diverse, cross-functional team to develop next generation CAR-T therapies. She is the Global Preclinical Research Lead for CTL019 and co-leads the joint research collaboration with the University of Pennsylvania to bring new cell therapies to clinical development for both hematological and solid tumors. Since she joined NIBR in 2004, Dr. Brogdon has developed broad expertise in antibody, small molecule and cell & gene therapy programs, most notably during the BLA submission, ODAC and approval of Kymriah. Dr. Brogdon holds a PhD in Immunology from Duke University and completed her postdoctoral training at Yale University.